ActiQs / Forskning

PUBLIKATIONSREGISTRET

Gå till forskningen.

Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.

Publikationer som ChEBI hänvisar till för epacadostat. Visa hela publikationsregistret

En publikationsträff är inte en slutsats. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.

Publikationer i urvalet

50 träffar

Bibliografisk träff 2023-10-20

Imidazo[2,1-b]thiazole based indoleamine-2,3-dioxygenase 1 (IDO1) inhibitor: Structure based design, synthesis, bio-evaluation and docking studies.

Singh R, Kumar R, Roy A, Behera PM, Atri AK, Kumar K, Manna D, Dixit A, Patil MT, Mankamna Kumari R, Nimesh S, Salunke DB.

Bioorg Med Chem Lett · research support, non-u.s. gov't; journal article · DOI 10.1016/j.bmcl.2023.129532

Bibliografisk träff 2023-04-11

Discovery of novel sulfonamide chromone-oxime derivatives as potent indoleamine 2,3-dioxygenase 1 inhibitors.

Wang K, Song LH, Liang QL, Zhang Y, Ma XL, Wang Q, Zhang HY, Jiang CN, Wei JH, Huang RZ.

Eur J Med Chem · journal article · DOI 10.1016/j.ejmech.2023.115349

Bibliografisk träff 2023-01-03

Dual Nicotinamide Phosphoribosyltransferase (NAMPT) and Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitors for the Treatment of Drug-Resistant Nonsmall-Cell Lung Cancer.

Wang K, Ye K, Zhang X, Wang T, Qi Z, Wang Y, Jiang S, Zhang K.

J Med Chem · research support, non-u.s. gov't; journal article · DOI 10.1021/acs.jmedchem.2c01954

Bibliografisk träff 2022-10-29

Discovery of novel hydroxyamidine based indoleamine 2,3-dioxygenase 1 (IDO1) and thioredoxin reductase 1 (TrxR1) dual inhibitors.

Zhou J, Yu LZ, Fan YL, Guo CH, Lv XM, Zhou ZY, Huang HD, Miao DD, Zhang SP, Li XY, Zhao PP, Liu XP, Hu WH, Zhang C.

Eur J Med Chem · journal article · DOI 10.1016/j.ejmech.2022.114860

Bibliografisk träff 2022-08-06

4,6-Disubstituted-1H-Indazole-4-Amine derivatives with immune-chemotherapy effect and in vivo antitumor activity.

Huo C, Luo Z, Ning X, Kang X, Yan Q, Guo Y, Li G, Wang Z, Li Y, Qian S.

Eur J Med Chem · journal article · DOI 10.1016/j.ejmech.2022.114625

Bibliografisk träff 2022-06-08

Dual-target inhibitors of indoleamine 2, 3 dioxygenase 1 (Ido1): A promising direction in cancer immunotherapy.

Zhang Y, Hu Z, Zhang J, Ren C, Wang Y.

Eur J Med Chem · review; journal article · DOI 10.1016/j.ejmech.2022.114524

Bibliografisk träff 2022-03-16

Discovery and biological evaluation of tanshinone derivatives as potent dual inhibitors of indoleamine 2, 3-dioxygenase 1 and tryptophan 2, 3-dioxygenase.

Liu J, Ren J, Yang K, Chen S, Yang X, Zhao QS.

Eur J Med Chem · journal article · DOI 10.1016/j.ejmech.2022.114294

Bibliografisk träff 2021-12-02

Discovery of the First Potent IDO1/IDO2 Dual Inhibitors: A Promising Strategy for Cancer Immunotherapy.

He X, He G, Chu Z, Wu H, Wang J, Ge Y, Shen H, Zhang S, Shan J, Peng K, Wei Z, Zou Y, Xu Y, Zhu Q.

J Med Chem · research support, non-u.s. gov't; journal article · DOI 10.1021/acs.jmedchem.1c01305

Bibliografisk träff 2021-11-02

Indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors and PROTAC-based degraders for cancer therapy.

Tang K, Wang B, Yu B, Liu HM.

Eur J Med Chem · review; journal article · DOI 10.1016/j.ejmech.2021.113967

Bibliografisk träff 2021-09-21

Discovery of novel IDO1 inhibitors targeting the protein's apo form through scaffold hopping from holo-IDO1 inhibitor.

Wu Y, Duan Q, Zou Y, Zhu Q, Xu Y.

Bioorg Med Chem Lett · research support, non-u.s. gov't; journal article · DOI 10.1016/j.bmcl.2021.128373

Bibliografisk träff 2021-08-13

Discovery of IDO1 inhibitors containing a decahydroquinoline, decahydro-1,6-naphthyridine, or octahydro-1H-pyrrolo[3,2-c]pyridine scaffold.

Yu W, Deng Y, Sloman D, Li D, Liu K, Fradera X, Lesburg CA, Martinot T, Doty A, Ferguson H, Richard Miller J, Knemeyer I, Otte K, Vincent S, Sciammetta N, Jonathan Bennett D, Han Y.

Bioorg Med Chem Lett · journal article · DOI 10.1016/j.bmcl.2021.128314

Bibliografisk träff 2021-07-22

Discovery of IACS-9779 and IACS-70465 as Potent Inhibitors Targeting Indoleamine 2,3-Dioxygenase 1 (IDO1) Apoenzyme.

Hamilton MM, Mseeh F, McAfoos TJ, Leonard PG, Reyna NJ, Harris AL, Xu A, Han M, Soth MJ, Czako B, Theroff JP, Mandal PK, Burke JP, Virgin-Downey B, Petrocchi A, Pfaffinger D, Rogers NE, Parker CA, Yu SS, Jiang Y, Krapp S, Lammens A, Trevitt G, Tremblay MR, Mikule K, Wilcoxen K, Cross JB, Jones P, Marszalek JR, Lewis RT.

J Med Chem · journal article · DOI 10.1021/acs.jmedchem.1c00679

Bibliografisk träff 2021-06-12

Design, synthesis and biological evaluation of exiguamine A analogues as IDO1 inhibitors.

Dong J, Pan X, Yang Y, Zhang G, Xiao Z, Liu Z.

Eur J Med Chem · journal article · DOI 10.1016/j.ejmech.2021.113631

Bibliografisk träff 2021-06-10

X-ray Structure-Guided Discovery of a Potent, Orally Bioavailable, Dual Human Indoleamine/Tryptophan 2,3-Dioxygenase (hIDO/hTDO) Inhibitor That Shows Activity in a Mouse Model of Parkinson's Disease.

Ning XL, Li YZ, Huo C, Deng J, Gao C, Zhu KR, Wang M, Wu YX, Yu JL, Ren YL, Luo ZY, Li G, Chen Y, Wang SY, Peng C, Yang LL, Wang ZY, Wu Y, Qian S, Li GB.

J Med Chem · research support, non-u.s. gov't; journal article · DOI 10.1021/acs.jmedchem.1c00303

Bibliografisk träff 2021-04-20

Parallel discovery of selective and dual inhibitors of tryptophan dioxygenases IDO1 and TDO2 with a newly-modified enzymatic assay.

Capochiani de Iudicibus R, Tomek P, Palmer BD, Tijono SM, Flanagan JU, Ching LM.

Bioorg Med Chem · research support, non-u.s. gov't; journal article · DOI 10.1016/j.bmc.2021.116160

Bibliografisk träff 2021-02-11

Furazans in Medicinal Chemistry.

Mancini RS, Barden CJ, Weaver DF, Reed MA.

J Med Chem · research support, non-u.s. gov't; review; journal article · DOI 10.1021/acs.jmedchem.0c01901

Bibliografisk träff 2021-01-28

Discovery and Preclinical Evaluation of BMS-986242, a Potent, Selective Inhibitor of Indoleamine-2,3-dioxygenase 1.

Cherney EC, Zhang L, Nara S, Zhu X, Gullo-Brown J, Maley D, Lin TA, Hunt JT, Huang C, Yang Z, Darienzo C, Discenza L, Ranasinghe A, Grubb M, Ziemba T, Traeger SC, Li X, Johnston K, Kopcho L, Fereshteh M, Foster K, Stefanski K, Fargnoli J, Swanson J, Brown J, Delpy D, Seitz SP, Borzilleri R, Vite G, Balog A.

ACS Med Chem Lett · rapid-communication; journal article · DOI 10.1021/acsmedchemlett.0c00668

Bibliografisk träff 2021-01-20

Discovery of Hydroxyamidine Derivatives as Highly Potent, Selective Indoleamine-2,3-dioxygenase 1 Inhibitors.

Jin F, Hu Q, Fei H, Lv H, Wang S, Gui B, Zhang J, Tu W, Zhang Y, Zhang L, Wan H, Zhang L, Hu B, Yang F, Bai C, He F, Zhang L, Tao W.

ACS Med Chem Lett · rapid-communication; journal article · DOI 10.1021/acsmedchemlett.0c00443

Bibliografisk träff 2021-01-13

A theranostic probe of indoleamine 2,3-dioxygenase 1 (IDO1) for small molecule cancer immunotherapy.

Wu Y, Zhang Y, Chen X, Hu Y, Dong G, Guo Y, Sheng C.

Eur J Med Chem · journal article · DOI 10.1016/j.ejmech.2021.113163

Bibliografisk träff 2020-08-14

Discovery and structure-activity relationship studies of 1-aryl-1H-naphtho[2,3-d][1,2,3]triazole-4,9-dione derivatives as potent dual inhibitors of indoleamine 2,3-dioxygenase 1 (IDO1) and trytophan 2,3-dioxygenase (TDO).

Pan S, Zhou Y, Wang Q, Wang Y, Tian C, Wang T, Huang L, Nan J, Li L, Yang S.

Eur J Med Chem · journal article · DOI 10.1016/j.ejmech.2020.112703

Bibliografisk träff 2020-07-15

Discovery of Potent and Orally Available Bicyclo[1.1.1]pentane-Derived Indoleamine-2,3-dioxygenase 1 (IDO1) Inhibitors.

Pu Q, Zhang H, Guo L, Cheng M, Doty AC, Ferguson H, Fradera X, Lesburg CA, McGowan MA, Miller JR, Geda P, Song X, Otte K, Sciammetta N, Solban N, Yu W, Sloman DL, Zhou H, Lammens A, Neumann L, Bennett DJ, Pasternak A, Han Y.

ACS Med Chem Lett · rapid-communication; journal article · DOI 10.1021/acsmedchemlett.0c00195

Bibliografisk träff 2020-03-29

Synthesis of novel tryptanthrin derivatives as dual inhibitors of indoleamine 2,3-dioxygenase 1 and tryptophan 2,3-dioxygenase.

Li Y, Zhang S, Wang R, Cui M, Liu W, Yang Q, Kuang C.

Bioorg Med Chem Lett · research support, non-u.s. gov't; journal article · DOI 10.1016/j.bmcl.2020.127159

Bibliografisk träff 2020-03-19

DNA-Encoded Library Technology-Based Discovery, Lead Optimization, and Prodrug Strategy toward Structurally Unique Indoleamine 2,3-Dioxygenase-1 (IDO1) Inhibitors.

Kazmierski WM, Xia B, Miller J, De la Rosa M, Favre D, Dunham RM, Washio Y, Zhu Z, Wang F, Mebrahtu M, Deng H, Basilla J, Wang L, Evindar G, Fan L, Olszewski A, Prabhu N, Davie C, Messer JA, Samano V.

J Med Chem · journal article · DOI 10.1021/acs.jmedchem.9b01799

Bibliografisk träff 2020-03-17

Discovery of Highly Potent Benzimidazole Derivatives as Indoleamine 2,3-Dioxygenase-1 (IDO1) Inhibitors: From Structure-Based Virtual Screening to <i>in Vivo</i> Pharmacodynamic Activity.

Serafini M, Torre E, Aprile S, Grosso ED, Gesù A, Griglio A, Colombo G, Travelli C, Paiella S, Adamo A, Orecchini E, Coletti A, Pallotta MT, Ugel S, Massarotti A, Pirali T, Fallarini S.

J Med Chem · research support, non-u.s. gov't; journal article · DOI 10.1021/acs.jmedchem.9b01809

Bibliografisk träff 2020-03-04

Implementation of the CYP Index for the Design of Selective Tryptophan-2,3-dioxygenase Inhibitors.

Parr BT, Pastor R, Sellers BD, Pei Z, Jaipuri FA, Castanedo GM, Gazzard L, Kumar S, Li X, Liu W, Mendonca R, Pavana RK, Potturi H, Shao C, Velvadapu V, Waldo JP, Wu G, Yuen PW, Zhang Z, Zhang Y, Harris SF, Oh AJ, DiPasquale A, Dement K, La H, Goon L, Gustafson A, VanderPorten EC, Mautino MR, Liu Y.

ACS Med Chem Lett · rapid-communication; journal article · DOI 10.1021/acsmedchemlett.0c00004

Bibliografisk träff 2020-02-15

Discovery of novel hydroxyamidine derivatives as indoleamine 2,3-dioxygenase 1 inhibitors with in vivo anti-tumor efficacy.

Liu C, Nan Y, Xia Z, Gu K, Chen C, Dong X, Ju D, Zhao W.

Bioorg Med Chem Lett · research support, non-u.s. gov't; journal article · DOI 10.1016/j.bmcl.2020.127038

Bibliografisk träff 2020-01-27

Discovery of Hydroxyamidine Based Inhibitors of IDO1 for Cancer Immunotherapy with Reduced Potential for Glucuronidation.

Steeneck C, Kinzel O, Anderhub S, Hornberger M, Pinto S, Morschhaeuser B, Braun F, Kleymann G, Hoffmann T.

ACS Med Chem Lett · rapid-communication; journal article · DOI 10.1021/acsmedchemlett.9b00572

Bibliografisk träff 2020-01-11

Design, synthesis, and biological evaluation of 1,2,5-oxadiazole-3-carboximidamide derivatives as novel indoleamine-2,3-dioxygenase 1 inhibitors.

Song X, Sun P, Wang J, Guo W, Wang Y, Meng LH, Liu H.

Eur J Med Chem · evaluation study; journal article · DOI 10.1016/j.ejmech.2020.112059

Bibliografisk träff 2019-12-21

Design, synthesis and biological evaluation of indole-2-carboxylic acid derivatives as IDO1/TDO dual inhibitors.

Cui G, Lai F, Wang X, Chen X, Xu B.

Eur J Med Chem · journal article · DOI 10.1016/j.ejmech.2019.111985

Bibliografisk träff 2019-12-17

Discovery of 5-(pyridin-3-yl)-1H-indole-4,7-diones as indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors.

Kong KM, Zhang JW, Liu BZ, Meng GR, Zhang Q.

Bioorg Med Chem Lett · research support, non-u.s. gov't; journal article · DOI 10.1016/j.bmcl.2019.126901